Successful treatment of the first adult case of ZMIZ1::ABL1-positive B cell lymphoblastic leukemia with dasatinib, chimeric antigen receptor T-cell therapy, and allogeneic hematopoietic stem cell transplantation

BCR::ABL1-like B cell lymphoblastic leukemia (B-ALL) is characterized by a gene-expression profile similar to that of BCR::ABL1-positive B-ALL, alterations of lymphoid transcription factor genes, and a poor outcome [1]. Kinase fusions are one of the most critical genetic features for this high-risk disease, and their detection may benefit the patients from targeted tyrosine kinase inhibitor (TKI) therapy [2]. BCR::ABL1-like B-ALL was initially introduced as a provisional entity in the revised 4th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours [3].

Source: Cancer Genetics and Cytogenetics - March 7, 2024 Category: Genetics & Stem Cells Authors: Xue Chen, Lili Yuan, Xiaoli Ma, Panxiang Cao, Fang Wang, Yang Zhang, Jiaqi Chen, Xian Zhang, Yanli Zhao, Hongxing Liu Source Type: research